SEC Comment Letter 0000000000-22-012448 to RenovoRx, Inc. (RNXT)
RenovoRx, Inc.
Date: Nov. 16, 2022 · CIK: 0001574094 · Accession: 0000000000-22-012448
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268302
Letter
United States securities and exchange commission logo November 16, 2022 Shaun Bagai Chief Executive Officer RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 Re:RenovoRx, Inc. Registration Statement on Form S-3 Filed November 10, 2022 File No. 333-268302 Dear Shaun Bagai: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Coke, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2022
Shaun Bagai
Chief Executive Officer
RenovoRx, Inc.
4546 El Camino Real, Suite B1
Los Altos, CA 94022
Re:RenovoRx, Inc.
Registration Statement on Form S-3
Filed November 10, 2022
File No. 333-268302
Dear Shaun Bagai:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Coke, Esq.